Hospital

Pharmacists can leverage their own identities to advocate for happier, healthier individuals within communities of different ethnic and socioeconomic backgrounds

Craig Sastic, PharmD, MBA, BCPS, discussed how he has seen the pharmacy field change throughout his career.

With health systems undergoing a necessary reevaluation of how they allocate their funding into the future, initial data support the need for them to offer a hospital-at-home option for patients they serve.

From finding mentors to maintaining a balanced lifestyle, these insights will empower students to navigate the ever-evolving world of pharmacy.

Confident pharmacists have traits that highlight their professionalism and effectiveness in their roles, while avoiding behaviors that could undermine the quality of their work.

A weekly dose of injectable lecanemab-irmb (Leqembi) could allow patients with Alzheimer disease to receive the drug at home instead of visiting an infusion center twice per month.

Vosoritide is a daily injection for children with achondroplasia who have open epiphyses, given under the skin and administered by a caregiver.

Viktor Grunwald, MD, PhD, discusses the post-hoc analysis of the phase 3 CLEAR trial investigating the combination treatment in the first-line setting for advanced renal cell carcinoma.

Compared to chemotherapy alone, amivantamab plus chemotherapy treatment with and without lazertinib had also demonstrated positive trends in OS and ORR in patients with NSCLC.

Many patients face significant challenges in accessing their specialty medications, which highlights the importance of pharmacy-deployed patient navigation programs designed to help resolve nonclinical, system-related barriers to care.

Patients with previously untreated HLA-A*02:01+ mUM saw improvements in OS, PFS, and ctDNA clearance.

Compared to placebo plus chemotherapy, nivolumab plus chemotherapy had also improved event-free survival and both pathological complete response and major pathologic response rates.

Vanderbilt Specialty Pharmacy and Takeda Oncology are reaching across silos and entering an innovative partnership to improve patient care across the entire medication journey.

Although a residency is beneficial for traditional career paths, a career can be more than working inside a pharmacy.

According to investigators, additional research is necessary to further understand how lutetium impacts overall survival in patients with metastatic prostate cancer.

Collaborating with patient advocacy organizations offers pharmacy students a unique opportunity to make a meaningful impact in health care.

BMS-986278 (Bristol Myers Squibb) is a potential first-in-class treatment for progressive pulmonary fibrosis and idiopathic pulmonary fibrosis.

Patients with HIV who were resistant to treatment with lenacapavir (Sunlenca; Gilead Sciences Inc) were found to have inadequate adherence to optimized background regimen or did not have a fully active antiretroviral.

The trial data showed ongoing clinical benefit in patients with advanced endometrial cancer who completed pembrolizumab and continued on lenvatinib vs chemotherapy alone.

Jack Mozloom, vice president of Public Affairs at the National Community Pharmacists Association (NCPA), speaks with Matt Seiler, general counsel at NCPA, about the current PBM litigation at the 2023 NCPA Convention.

Compared to chemotherapy alone, amivantamab plus chemotherapy had a better objective response rate and prolonged progression-free survival and overall survival.

Nirsevimab-alip (Beyfortus; Sanofi and AstraZeneca) is a monoclonal antibody approved to prevent against respiratory syncytial virus (RSV) lower respiratory tract disease in newborns and infants under 8 months of age born during or entering their first RSV season.

Taking pharmacists out of the dispensing setting and placing them in communities as educators on drug safety is reaping rewards.

This is the first phase 3 trial to evaluate a KRAS G12C-inhibitor plus an anti-epidermal growth factor receptor antibody for this type of colorectal cancer.

The novel combination met the co-primary endpoints of progression-free survival and overall survival during the CheckMate -901 trial, also demonstrating sizeable improvement in objective response.

Risk of long COVID was 3 times higher in those who had pre-existing conditions and a short sleep duration, compared to those with no pre-existing conditions and adequate sleep.

mRNA-1083 is an investigational combination vaccine designed to prevent influenza and COVID-19.

Not only did taletrectinib shrink tumors in 92% of patients who were tyrosine kinase inhibitor -naïve, but 89.5% of patients continued to respond to treatment at 12 months.